Evidence map›Paper›PMID 31205619›Full record

ReviewComputational and structural biotechnology journal2019

Application of PD-1 Blockade in Cancer Immunotherapy.

Xiaomo Wu, Zhongkai Gu, Yang Chen, Borui Chen, Wei Chen, Liqiang Weng, Xiaolong Liu

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Computational and structural biotechnology journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06798376 (The Comparison of Different Cycles of PD-1 Blockades Combined with Chemotherapy As Neoadjuvant Therapy for Patients with Advanced Gastric Cancer), which is not on this map. Cited by 322 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
322citing papers in PubMed, 6 pooled it
26.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06798376 recruitingnot on this mapstarted 2025, after this paper: background citation

The Comparison of Different Cycles of PD-1 Blockades Combined with Chemotherapy As Neoadjuvant Therapy for Patients with Advanced Gastric Cancer

TypeobservationalSponsorChinese PLA General HospitalRan2025 to 2025Enrolled300ConditionsGastric AdenocarcinomaArms≤4 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy, ≥5 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy, Gastrectomy
3 · Its place in the literature

Who cites it

322 citing papers in PubMed, 6 syntheses or guidelines pooled it, 540 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Global characteristics and trends in research onFrontiers in microbiology · 2023
    Pooled it
  7. Article
  8. Prognostic Value of FST and Relevance to Immune Infiltration in Head and Neck Squamous Cell Carcinoma.World journal of otorhinolaryngology - head and neck surgery · 2026
    Article
  9. Therapeutic bacteria-trained NK cells confer long-term protection against cancer metastasis.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

262 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Xiaomo WuDermatology Institute of Fuzhou, Dermatology Hospital of Fuzhou, Xihong Road 243, Fuzhou 350025, PR China.
Zhongkai GuThe Institute of Biomedical Sciences, Fudan University, Mingdao Building, Dongan Road 131, Shanghai 200032, PR China.
Yang ChenDermatology Institute of Fuzhou, Dermatology Hospital of Fuzhou, Xihong Road 243, Fuzhou 350025, PR China.
Borui ChenDermatology Institute of Fuzhou, Dermatology Hospital of Fuzhou, Xihong Road 243, Fuzhou 350025, PR China.
Wei ChenLiver Disease Center, The First Affiliated Hospital of Fujian Medical University, Chazhong Road 20, Fuzhou 350005, PR China.
Liqiang WengDermatology Institute of Fuzhou, Dermatology Hospital of Fuzhou, Xihong Road 243, Fuzhou 350025, PR China.
Xiaolong LiuThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Xihong Road 312, Fuzhou 350025, PR China.
Fuzhou Dermatosis Prevention Hospital · CNFujian Medical University · CNFudan University · CNUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The programmed cell death protein 1 (PD-1) pathway has received considerable attention due to its role in eliciting the immune checkpoint response of T cells, resulting in tumor cells capable of evading immune surveillance and being highly refractory to conventional chemotherapy. Application of anti-PD-1/PD-L1 antibodies as checkpoint inhibitors is rapidly becoming a promising therapeutic approach in treating tumors, and some of them have successfully been commercialized in the past few years. However, not all patients show complete responses and adverse events have been noted, suggesting a better understanding of PD-1 pathway mediated immunosuppression is needed to predict patient response and improve treatment efficacy. Here, we review the progresses on the studies of the mechanistic role of PD-1 pathway in the tumor immune evasion, recent clinical development and commercialization of PD-1 pathway inhibitors, the toxicities associated with PD-1 blockade observed in clinical trials as well as how to improve therapeutic efficacy and safety of cancer immunotherapy.

Indexed as

5-AZA-dC, 5-aza-2′-deoxycytidineADCC, Antibody-dependent cellular cytotoxicityAEs, Adverse eventsAP1, Activator protein 1APCs, Antigen presenting cellsASCT, Autologous stem cell transplantationB2M, β2 microglobulinBATF, Basic leucine zipper transcriptional factor ATF-likeBICR, Blinded Independent Central ReviewBV, Brentuximab vedotinCC, Cervical cancerCheckpoint blockadecHL, Classical Hodgkin lymphomaCRC, Colorectal cancerCTLA-4, Cytotoxic T-lymphocyte–associated antigen 4cTnI, Cardiac troponin ICXCL9, C-X-C motif chemokine ligand 9DCM, Dilated cardiomyopathyDCs, Dendritic cellsdMMR, DNA mismatch repair deficiencyDNMT, DNA methyltransferaseDOR, Duration overall responseDZNep, 3-Deazaneplanocin AERK, Extracellular signal–regulated kinaseEZH2, Enhancer of zeste homolog 2GC, Gastric cancerGEJ, GASTRIC or gastroesophageal junctionHCC, Hepatocellular carcinomaHNSCC, Head and neck squamous cell carcinomaHR, Hazard ratioICC, Investigator-choice chemotherapyICOS, Inducible T-cell co-stimulatorIFN, InterferonIHC, ImmunohistochemistryImmune surveillanceImmunotherapyIrAEs, Immune related adverse eventsITIM, Immune-receptortyrosine-based inhibitory motifITSM, Immune-receptortyrosine-based switch motifITT, Intention-to-treatJMJD3, Jumonji Domain-Containing Protein 3LAG3, Lymphocyte-activation gene 3LCK, Tyrosine-protein kinase LckMAP, Mitogen-activated proteinMCC, Merkel cell carcinomaMHC, Major histocompatibilityMSI-H, Microsatellite instability-highNFAT, Nuclear factor of activated T cellsNF-κB, Nuclear factor-κBNSCLC, Non-small cell lung cancerORR, Overall response rateOS, Overall survivalPD-1PD-1, Programmed cell death 1PD-L1PD-L1, Programmed death-ligand 1PFS, Progression-free survivalPI3K, Phosphoinositide 3-kinasePKC, Protein kinase CPMBCL, Primary mediastinal large B-cell lymphomaPRC2, Polycomb repressive complex 2PTEN, Phosphatase and tensin homologPTPs, Protein tyrosine phosphatasesRCC, Renal cell carcinomaSCLC, Small cell lung cancerSHP2, Src homology 2 domain-containing phosphatase 2SIRPα, Signal-regulatory protein alphaTCR, T-cell receptorTGF, Transforming growth factorTIICs, Tumor infiltrating immune cellsTILs, Tumor-infiltrating lymphocytesTIM3, T-cell immunoglobulin and mucin-domain containing-3TMB, Tumor mutation burdenTME, Tumor microenvironmentUC, Urothelial carcinomaVEGF, Vascular endothelial growth factorZAP70, Zeta-chain-associated protein kinase 70

Identifiers

PMID31205619
PMCPMC6558092
OpenAlexW2945219971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.